Health Trials

Osteosarcoma Recurrent

3

Review clinical trials related to Osteosarcoma Recurrent. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

Participants needed: 25
Trial details
Phase: Phase 1, Phase 2Age: 3+Biological sex: AllType: InterventionalSponsor: Fundación de investigación HMUpdated: Jun 4, 2026Locations: 1
Eligibility criteria

18 months - 18 years of age at the time of the initial diagnosis. [+22]

Previous significant drug-induced hepatitis toxicity experienced in the past tha... [+7]

Read more
Status: Recruiting

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.

Participants needed: 24
Trial details
Phase: Phase 1Age: 1-30Biological sex: AllType: InterventionalSponsor: Emory UniversityUpdated: Jun 2, 2026Locations: 1
Eligibility criteria

All participants with relapsed or refractory osteosarcoma are eligible, provided... [+18]

CNS disease: Patients with a history of intraparenchymal CNS disease (osteosarco... [+16]

Read more
Status: Recruiting

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

The purpose of this study is to determine the feasibility of administering DL-alpha-difluoromethylornithine (DFMO) to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.

Participants needed: 15
Trial details
Phase: Phase 1, Phase 2Age: Up to 39Biological sex: AllType: InterventionalSponsor: Montefiore Medical CenterUpdated: May 14, 2026Locations: 1
Eligibility criteria

Patients < 40 years of age at the time of enrollment [+11]

Pregnant or breastfeeding females. Men and women of childbearing potential and t... [+2]

Read more